NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
38 trialsNCT04699188 2026-03-18
KontRASt-01
Novartis
Phase 1/2 Active not recruiting
NCT05635708 2026-03-18
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Active not recruiting
NCT06487858 2026-03-18
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT06422520 2026-02-23
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04649385 2026-02-20
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT05651022 2026-01-13
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06866548 2025-12-04
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT05661955 2025-11-21
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT05789069 2025-11-21
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT06010303 2025-11-17
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Active not recruiting
NCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT05909904 2025-10-07
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
BeiGene
Phase 2 Active not recruiting
NCT05609370 2025-10-02
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
BeiGene
Phase 1/2 Active not recruiting
NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
NCT05632939 2025-09-10
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
AskGene Pharma, Inc.
Phase 1/2 Active not recruiting
NCT04387084 2025-09-05
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05604560 2025-07-23
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Active not recruiting
NCT04746924 2025-06-24
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeiGene
Phase 3 Active not recruiting
NCT05319574 2025-06-12
SACTION01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06009861 2025-06-06
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Peking University Hospital of Stomatology
Phase 2 Active not recruiting
NCT05840016 2025-05-02
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Akeso
Phase 3 Active not recruiting
NCT05167071 2025-04-27
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Active not recruiting
NCT06056804 2025-04-02
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Active not recruiting
NCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06239532 2024-11-21
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT05519865 2024-08-07
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Active not recruiting
NCT04727996 2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2 Active not recruiting
NCT05211232 2024-04-18
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04776590 2024-04-12
CRISEC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Active not recruiting